Hospital
Palomar Health
Palomar Health was paid $46.68M by Medicaid between Jan 2018 and Dec 2024, across 180 billing codes. Its largest line is 0450, Emergency room services — 18% of everything it billed.
33Billing provider infoPALOMAR HEALTH
POWAY, CA 92064
POWAY, CA 92064
33aNPI1376513754assigned 01/26/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$46.68M
24GClaims473,610
24DCodes billed180
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in California
Rank by total paid#3 of 33
Median peer was paid$361K
This provider vs. median129×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,438 | $7.26M | |
| 2019 | 57,888 | $5.81M | |
| 2020 | 48,727 | $5.48M | |
| 2021 | 64,485 | $5.99M | |
| 2022 | 83,320 | $7.37M | |
| 2023 | 88,171 | $7.82M | |
| 2024incomplete | 70,581 | $6.96M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 18% | 24,159 | 21,802 | $8.54M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 24,803 | 22,730 | $6.87M |
| J3490 | Unclassified drugs | 10% | 34,155 | 16,341 | $4.84M |
| 80048 | Basic metabolic panel (calcium, ionized) | 6.7% | 24,627 | 22,072 | $3.15M |
| 80053 | Comprehensive metabolic panel | 4.5% | 11,674 | 11,035 | $2.11M |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 4.1% | 6,233 | 5,885 | $1.91M |
| 97139 | 2.2% | 22,044 | 3,304 | $1.04M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 3,660 | 3,569 | $844K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 4,916 | 4,772 | $806K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.7% | 5,326 | 4,983 | $775K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.6% | 3,530 | 3,346 | $766K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.6% | 4,490 | 4,140 | $751K |
168 more codes
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.5% | 4,493 | $722K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.5% | 4,102 | $687K |
| 0250 | 1.4% | 12,867 | $660K | |
| 99499 | 1.3% | 5,928 | $603K | |
| 71045 | Radiologic examination, chest; single view | 1.3% | 13,617 | $601K |
| J1170 | Injection, hydromorphone, up to 4 mg | 1.2% | 2,615 | $570K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1.0% | 1,747 | $475K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 16,640 | $470K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,192 | $448K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,889 | $411K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,772 | $366K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,732 | $365K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,551 | $314K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,802 | $307K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,569 | $304K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,108 | $275K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 816 | $270K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,680 | $266K |
| 84703 | <1% | 8,973 | $255K | |
| 81001 | <1% | 13,156 | $240K | |
| 80076 | <1% | 11,068 | $220K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,438 | $200K |
| 73610 | <1% | 931 | $194K | |
| 97750 | <1% | 1,859 | $189K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 912 | $182K |
| 73630 | <1% | 1,128 | $176K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,679 | $174K |
| 84484 | <1% | 11,194 | $172K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,804 | $169K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,315 | $155K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,320 | $153K |
| 0270 | <1% | 4,659 | $153K | |
| 73562 | <1% | 974 | $152K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,535 | $146K |
| 83690 | <1% | 12,176 | $137K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,165 | $136K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,319 | $135K |
| 84702 | <1% | 1,576 | $126K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,128 | $126K |
| 81003 | <1% | 6,181 | $113K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 712 | $111K |
| 85027 | <1% | 8,982 | $104K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,689 | $100K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,607 | $97K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,422 | $96K |
| 87077 | <1% | 2,456 | $95K | |
| 73030 | <1% | 503 | $94K | |
| 73130 | <1% | 552 | $80K | |
| 76830 | Ultrasound, transvaginal | <1% | 994 | $79K |
| 90715 | <1% | 211 | $78K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 649 | $76K |
| 72131 | <1% | 619 | $73K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,283 | $62K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,056 | $62K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,381 | $60K |
| 86901 | <1% | 2,154 | $60K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 711 | $59K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 622 | $55K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 353 | $47K |
| 93971 | <1% | 645 | $43K | |
| 87503 | <1% | 867 | $43K | |
| 87040 | <1% | 1,275 | $35K | |
| 83605 | <1% | 2,647 | $32K | |
| 0762 | <1% | 89 | $32K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,555 | $31K |
| 97799 | <1% | 653 | $31K | |
| 82550 | <1% | 1,971 | $29K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 696 | $28K |
| 83880 | <1% | 2,077 | $27K | |
| 76801 | <1% | 619 | $27K | |
| 73110 | <1% | 195 | $27K | |
| 83735 | <1% | 3,366 | $26K | |
| 72128 | <1% | 258 | $25K | |
| 85379 | <1% | 2,111 | $25K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 3,837 | $25K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 44 | $24K |
| 85610 | <1% | 4,786 | $24K | |
| 87186 | <1% | 1,734 | $23K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 218 | $22K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,540 | $22K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 29 | $20K |
| 70498 | <1% | 248 | $19K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 162 | $18K |
| 85730 | <1% | 2,405 | $17K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 273 | $14K |
| Z7502 | <1% | 424 | $14K | |
| 70496 | <1% | 193 | $13K | |
| 86140 | <1% | 1,597 | $12K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 197 | $11K |
| 86885 | <1% | 849 | $10K | |
| 97014 | <1% | 83 | $10K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,217 | $10K |
| J1815 | Injection, insulin, per 5 units | <1% | 63 | $10K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 213 | $9K |
| 73502 | <1% | 100 | $8K | |
| 94760 | <1% | 2,139 | $8K | |
| 82962 | <1% | 317 | $7K | |
| 82553 | <1% | 140 | $7K | |
| 77080 | <1% | 166 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 175 | $6K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 308 | $6K |
| 93970 | <1% | 76 | $6K | |
| 76770 | <1% | 52 | $6K | |
| 86900 | <1% | 940 | $6K | |
| 72100 | <1% | 39 | $6K | |
| 99070 | <1% | 2,102 | $5K | |
| 0761 | <1% | 67 | $5K | |
| 71250 | <1% | 44 | $5K | |
| 90686 | <1% | 13 | $5K | |
| 85652 | <1% | 1,074 | $5K | |
| 73140 | <1% | 14 | $4K | |
| 73590 | <1% | 41 | $4K | |
| 84100 | <1% | 782 | $4K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 56 | $4K |
| 0258 | <1% | 540 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 152 | $4K |
| 85007 | <1% | 652 | $4K | |
| 97116 | <1% | 475 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 40 | $3K |
| 84145 | <1% | 199 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 93 | $3K |
| 80061 | Lipid panel | <1% | 911 | $3K |
| 0451 | <1% | 54 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 63 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 175 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,110 | $2K |
| 0255 | <1% | 100 | $2K | |
| Z7610 | <1% | 198 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 141 | $2K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 28 | $2K |
| 87070 | <1% | 29 | $2K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 29 | $2K |
| 97161 | <1% | 172 | $2K | |
| 74018 | <1% | 27 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 126 | $2K |
| 76536 | <1% | 14 | $2K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 62 | $2K |
| 70486 | <1% | 12 | $2K | |
| 71010 | <1% | 31 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 27 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 171 | $1K |
| 0710 | <1% | 12 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 216 | $1K |
| 86308 | <1% | 12 | $1K | |
| 87081 | <1% | 14 | $1K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 73 | $947.78 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,707 | $863.10 |
| 82805 | <1% | 42 | $862.42 | |
| 94644 | <1% | 49 | $749.13 | |
| 92526 | <1% | 13 | $624.83 | |
| 97162 | <1% | 49 | $603.38 | |
| 82728 | <1% | 69 | $586.62 | |
| 94645 | <1% | 51 | $552.02 | |
| 0324 | <1% | 12 | $549.18 | |
| 84439 | <1% | 170 | $503.05 | |
| 74022 | <1% | 12 | $484.82 | |
| 83615 | <1% | 77 | $434.45 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 30 | $389.47 |
| 82607 | <1% | 102 | $374.10 | |
| 0272 | <1% | 43 | $343.57 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 103 | $194.48 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 27 | $166.13 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 42 | $162.95 |
| 82248 | <1% | 15 | $107.75 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 16 | $87.01 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 15 | $4.75 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 19 | $4.12 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANSEN, DIANE (PRESIDENT AND CEO)
Parent organizationPALOMAR HEALTH
| Provider | Location | Paid |
|---|---|---|
| Palomar Health | Escondido, CA | $144.14M |
| Palomar Health | Escondido, CA | $42.20M |
| MT Graham Regional Medical Center INC | Safford, AZ | $5.92M |
| Palomar Health | San Marcos, CA | $2.84M |
| Palomar Health | Escondido, CA | $1.20M |
| Palomar Health | Poway, CA | $528K |
| Speech Center of Southern Arizona | Tucson, AZ | $281K |
| Palomar Health | Escondido, CA | $40K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.